We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The UK’s National Institute for Health and Care Excellence is recommending reimbursement of Novartis’ drug combination Mekinist and Tafinlar for treating unresectable or metastatic melanoma in patients with BRAF V600 mutations. Read More